PDCD1 and metastatic melanoma: It was showed that metastatic melanoma patients receiving PD-1 inhibitor and concurrent radiotherapy had higher objective response rate than patients receiving PD-1 inhibitor monotherapy (64.7% vs. 33.3%, P = 0.02) [63].